Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an <scp>ELN‐DAVID</scp> expert panel

Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, Richard Dillon, Konstanze Döhner, Sylvie D. Freeman, Christopher S. Hourigan, Gerrit J. Ossenkoppele, Gail J. Roboz, Marion Subklewe, Christian Thiede, Isabell Arnhardt, Peter J. M. Valk, Adriano Venditti, Andrew H. Wei, Roland B. Walter, Michael Heuser

Open source

DOI: 10.1002/ajh.27087
Published: 2023-09-06
Container: American Journal of Hematology
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ajh.27087,
  title = {Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an <scp>ELN‐DAVID</scp> expert panel},
  author = {Farhad Ravandi and Jacqueline Cloos and Francesco Buccisano and Richard Dillon and Konstanze Döhner and Sylvie D. Freeman and Christopher S. Hourigan and Gerrit J. Ossenkoppele and Gail J. Roboz and Marion Subklewe and Christian Thiede and Isabell Arnhardt and Peter J. M. Valk and Adriano Venditti and Andrew H. Wei and Roland B. Walter and Michael Heuser},
  year = {2023},
  journal = {American Journal of Hematology},
  doi = {10.1002/ajh.27087},
  url = {https://doi.org/10.1002/ajh.27087}
}

RIS

TY  - JOUR
TI  - Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an <scp>ELN‐DAVID</scp> expert panel
AU  - Farhad Ravandi
AU  - Jacqueline Cloos
AU  - Francesco Buccisano
AU  - Richard Dillon
AU  - Konstanze Döhner
AU  - Sylvie D. Freeman
AU  - Christopher S. Hourigan
AU  - Gerrit J. Ossenkoppele
AU  - Gail J. Roboz
AU  - Marion Subklewe
AU  - Christian Thiede
AU  - Isabell Arnhardt
AU  - Peter J. M. Valk
AU  - Adriano Venditti
AU  - Andrew H. Wei
AU  - Roland B. Walter
AU  - Michael Heuser
PY  - 2023
JO  - American Journal of Hematology
DO  - 10.1002/ajh.27087
UR  - https://doi.org/10.1002/ajh.27087
ER  -

APA

Ravandi, F., Cloos, J., Buccisano, F., Dillon, R., Döhner, K., Freeman, S. D., Hourigan, C. S., Ossenkoppele, G. J., Roboz, G. J., Subklewe, M., Thiede, C., Arnhardt, I., Valk, P. J. M., Venditti, A., Wei, A. H., Walter, R. B., & Heuser, M. (2023). Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an <scp>ELN‐DAVID</scp> expert panel. American Journal of Hematology. https://doi.org/10.1002/ajh.27087

Source records

crossref · retrieved 2026-09-27T12:39:22.280Z